Amol Akhade: What is interesting at ESMO GI24? NEST 1 trial
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:
“What is interesting at European Society for Medical Oncology (ESMO) GI24 ?
Neo adjuvant Botensilimab (BOT) plus Balstilimab (BAL) for rectal cancer – NEST 1 trial .
Is it time for a new staging system for colon adenocarcinoma?
Neo adjuvant Rogerafenib and Nivolumab plus short course radiotherapy for stage 2 /3 rectal cancer .
Final analysis of Keynote 585.”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata memorial hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
